Cargando…
Verteporfin ameliorates fibrotic aspects of Dupuytren’s disease nodular fibroblasts irrespective the activation state of the cells
Dupuytren’s disease is a chronic, progressive fibroproliferative condition of the hand fascia which results in digital contraction. So far, treatments do not directly interfere with the (myo)fibroblasts that are responsible for the formation of the collagen-rich cords and its contraction. Here we in...
Autores principales: | Puerta Cavanzo, Nataly, Riesmeijer, Sophie A., Holt-Kedde, Iris L., Werker, Paul M. N., Piersma, Bram, Olinga, Peter, Bank, Ruud A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386017/ https://www.ncbi.nlm.nih.gov/pubmed/35977978 http://dx.doi.org/10.1038/s41598-022-18116-9 |
Ejemplares similares
-
Macromolecular Crowding as a Tool to Screen Anti-fibrotic Drugs: The Scar-in-a-Jar System Revisited
por: Puerta Cavanzo, Nataly, et al.
Publicado: (2021) -
Ethnic differences in prevalence of Dupuytren disease can partly be explained by known genetic risk variants
por: Riesmeijer, Sophie A., et al.
Publicado: (2019) -
Matrix and cell phenotype differences in Dupuytren’s disease
por: van Beuge, Marike M., et al.
Publicado: (2016) -
Further evidence of the involvement of the Wnt signaling pathway in Dupuytren’s disease
por: ten Dam, Evert-Jan P. M., et al.
Publicado: (2015) -
Verteporfin as a Medical Treatment in Peyronie’s Disease
por: Mohede, Daan C.J., et al.
Publicado: (2018)